BODISEN BIOTECH, INC.
Audited Results for the year ended 31 December 2007
Review and Extracts of the Form 10-K as required by the Securities and Exchange Commission
Consolidated Statements of Operations and other Comprehensive Income (Loss)
For the years ended December 31, 2007 and 2006
|
Years ended
December 31, |
|
2007 |
2006 |
|
$ |
$ |
Net Revenue |
12,108,579 |
43,626,984 |
|
|
|
Cost of Revenue |
6,762,370 |
26,543,163 |
|
---------------- |
---------------- |
Gross profit |
5,346,209 |
17,083,821 |
Operating expenses |
|
|
Selling expenses |
1,772,544 |
1,972,076 |
General and administrative expenses |
29,137 |
1,553,374 |
|
---------------- |
---------------- |
Total operating expenses |
30,909,704 |
3,525,450 |
|
---------------- |
---------------- |
Income (loss) from operations |
(25,563,495) |
13,558,371 |
Non-operating income (expense): |
|
|
Other income (expense) |
(69,519) |
612,584 |
Interest income |
348,113 |
240,527 |
Interest expense |
(4,318) |
(680,655) |
|
---------------- |
---------------- |
Total non-operating income (expense) |
274,276 |
172,456 |
|
---------------- |
---------------- |
Loss before provision for income taxes |
(25,289,219) |
13,730,827 |
Provision for income taxes |
38,713 |
- |
|
---------------- |
---------------- |
Net income (loss) |
(25,327,392) |
13,730,827 |
Other comprehensive income |
|
|
Foreign currency translation gain (loss) |
3,349,735 |
1,210,466 |
Unrealised gain (loss) on marketable equity security |
7,739,130 |
(309,565) |
|
---------------- |
---------------- |
Comprehensive Income (loss) |
(14,238,527) |
14,631,728 |
|
========= |
========= |
Weighted average shares outstanding : |
|
|
Basic |
18,310,250 |
17,966,090 |
|
========= |
========= |
Diluted |
18,310,250 |
18,072,433 |
|
========= |
========= |
Earnings per share: |
|
|
Basic |
(1.38) |
0.76 |
|
========= |
========= |
Diluted |
(1.38) |
0.76 |
|
========= |
========= |
Bodisen Biotech, Inc. and Subsidiaries
Consolidated Statement of Stockholders' Equity
For the years ended December 31, 2007 and 2006
|
|
|
Other |
|
Retained
/Earnings |
Total |
|
Common Stock |
Additional paid |
Comprehensive |
Statutory |
(Accumulated |
Stockholders* |
|
Shares |
Amount |
in capital |
Income |
Reserve |
Deficit) |
Equity |
|
|
|
|
|
|
|
|
Balance, December 31, 2005 |
16,120,902 |
1,613 |
12,082,793 |
4,531,009 |
2,366,931 |
12,434,757 |
31,417,103 |
|
|
|
|
|
|
|
|
Sale of common stock for cash, net of offering costs of $6,132,708 |
2,024,015 |
202 |
20,549,602 |
|
|
|
20,549,804 |
|
|
|
|
|
|
|
|
Exercise of warrants for cash |
165,333 |
16 |
1,220,144 |
|
|
|
1,220,160 |
|
|
|
|
|
|
|
|
Value of vested options issued directors |
|
|
7,523 |
|
|
|
7,523 |
|
|
|
|
|
|
|
|
Change in foreign currency translation gain |
|
|
|
1,210,466 |
|
|
1,210,466 |
|
|
|
|
|
|
|
|
Change in unrealised gain on marketable equity security |
|
|
|
(309,565) |
|
|
(309,565) |
|
|
|
|
|
|
|
|
Net income for the year ended December 31, 2006 |
|
|
|
|
|
13,730,827 |
13,730,827 |
|
|
|
|
|
|
|
|
Transfer to statutory reserve |
|
|
|
|
1,947,557 |
1,947,557 |
- |
|
--------------- |
-------------- |
--------------- |
--------------- |
--------------- |
--------------- |
--------------- |
Balance, December 31, 2006 |
18,310,250 |
1,831 |
33,860,062 |
5,431,910 |
4,314,488 |
24,218,027 |
67,826,318 |
|
|
|
|
|
|
|
|
Change in foreign currency translation gain |
|
|
|
3,349,735 |
|
|
3,349,735 |
|
|
|
|
|
|
|
|
Change in unrealised gain on marketable equity security |
|
|
|
7,739,130 |
|
|
7,739,130 |
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
(25,327,392) |
(25,327,392) |
|
|
|
|
|
|
|
|
Transfer to statutory reserve |
|
|
|
|
- |
- |
- |
|
--------------- |
-------------- |
--------------- |
--------------- |
--------------- |
--------------- |
--------------- |
Balance, December 31, 2007 |
18,310,250 |
1,831 |
33,860,062 |
16,520,775 |
4,314,488 |
(1,109,365) |
53,587,791 |
|
======== |
======== |
======== |
======== |
======== |
======== |
======== |
Consolidated Balance Sheet
As of December 31, 2007 and 2006
|
December 31
2007 |
December 31
2006 |
|
$ |
$ |
ASSETS |
|
|
CURRENT ASSETS: |
|
|
Cash & cash equivalents |
617,406 |
11,824,327 |
Accounts receivable, net of allowance for doubtful accounts of $25,447,689 and $659,653 |
618,052 |
18,875,368 |
Other receivable |
2,292,763 |
888,230 |
Inventory |
1,179,448 |
1,794,585 |
Advances to suppliers |
9,741,090 |
12,662,139 |
Prepaid expense and other current assets |
5,066,015 |
195,821 |
|
------------------- |
------------------- |
Total current assets |
19,514,774 |
46,240,470 |
|
|
|
PROPERTY AND EQUIPMENT, net |
5,306,254 |
5,195,283 |
CONSTRUCTION IN PROGRESS |
7,722,756 |
3,669,807 |
MARKETABLE SECURITY |
14,239,999 |
6,500,869 |
INTANGIBLE ASSETS, net |
2,050,652 |
2,054,346 |
OTHER ASSETS |
3,720,785 |
3,553,433 |
LOAN RECEIVABLE |
2,439,275 |
1,982,410 |
|
------------------- |
------------------- |
TOTAL ASSETS |
54,994,495 |
69,196,618 |
|
========== |
========== |
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
CURRENT LIABILITIES: |
|
|
Accounts payable |
1,186,768 |
1,022,352 |
Accrued expenses |
219,936 |
347,948 |
|
------------------- |
------------------- |
Total current liabilities |
1,406,704 |
1,370,300 |
|
|
|
STOCKHOLDERS' EQUITY: |
|
|
Preferred stock, $0.0001 per share; authorised 5,000,000 shares; nil issued and outstanding |
|
|
Common stock, $0.0001 per share; authorised 30,000,000 shares; issued and outstanding 18,310,250 and 18,310,250 |
1,831 |
1,831 |
Additional paid-in capital |
33,860,062 |
33,860,062 |
Other comprehensive income |
16,520,775 |
5,431,910 |
Statutory reserve |
4,314,488 |
4,314,488 |
Retained earnings (accumulated deficit) |
(1,109,365) |
24,218,027 |
|
------------------- |
------------------- |
Total stockholders' equity |
53,587,791 |
67,826,318 |
|
------------------- |
------------------- |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
54,994,495 |
69,196,618 |
|
========== |
========== |
Consolidated Statements of Cash Flows
For the years ended December 31, 2007 and 2006
|
Years Ended December 31, |
|
2007 |
2006 |
|
$ |
$ |
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
Net income (loss) |
(25,327,392) |
13,730,827 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |
|
|
Depreciation and amortization |
478,027 |
455,318 |
Amortisation of debt discounts |
- |
603,886 |
Exchange gain (loss) |
- |
(451,867) |
Value of vested option issued to directors |
|
7,523 |
Allowance for bad debts |
23,777,908 |
- |
(Increase)/decrease in assets: |
|
|
Accounts receivable |
(4,965,277) |
(10,906,475) |
Other receivable and Loan Receivable |
(1,596,224) |
(1,759,543) |
Inventory |
711,601 |
(562,179) |
Deposits |
(100,501) |
- |
Advances to suppliers |
3,656,973 |
(7,775,011) |
Prepaid expense |
(4,566,786) |
(133,967) |
Other assets |
|
3,482 |
Increase/(decrease) in current liabilities: |
|
|
Accounts payable |
144,607 |
959,335 |
Other payable |
(145,661) |
(15,168) |
Accrued expenses |
- |
(76,258) |
|
----------------- |
----------------- |
Net cash provided by (used in) operating activities |
(7,932,725) |
(5,920,097) |
|
----------------- |
----------------- |
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
Acquisition of property and equipment |
(94,607) |
(451,358) |
Additions to construction in progress |
(3,648,750) |
(19,696,321) |
Investments |
|
- |
Acquisition of other assets |
- |
(3,481,672) |
|
----------------- |
----------------- |
Net cash used in investing activities |
3,743,357 |
(5,629,351) |
|
----------------- |
----------------- |
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
Payments on note payable |
- |
(5,000,000) |
Loans made to officers |
- |
- |
Repayments of loans to officers |
- |
- |
Proceeds from issuance of convertible note |
- |
- |
Proceeds from issuance of not payable |
- |
- |
Proceeds from issuance of common stock |
- |
26,682,511 |
Payment of offering costs |
- |
(6,132,707) |
Proceeds from the exercise of warrants |
- |
1,220,160 |
|
----------------- |
----------------- |
Net cash provided by financing activities |
- |
16,769,964 |
|
----------------- |
----------------- |
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
469,161 |
326,914 |
|
----------------- |
----------------- |
NET INCREASE/(DECREASE) IN CASH & CASH EQUIVALENTS |
(11,206,921) |
5,547,430 |
|
|
|
CASH & CASH EQUIVALENTS, BEGINNING OF YEAR |
11,824,327 |
6,276,897 |
|
----------------- |
----------------- |
CASH & CASH EQUIVALENTS, end OF YEAR |
617,406 |
11,824,327 |
|
========= |
========= |
|
|
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |
|
|
Interest paid |
- |
112,500 |
|
========= |
========= |
Income taxes paid |
- |
- |
|
========= |
========= |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1 - Organization and Basis of Presentation
Organization and Line of Business
Yang Ling Bodisen Biology Science and Technology Development Company Limited (※BBST§) was founded in the People*s Republic of China on August 31, 2001. BBST, located in Yang Ling Agricultural High-Tech Industries Demonstration Zone, is primarily engaged in developing, manufacturing and selling pesticides and compound organic fertilizers in the People*s Republic of China.
On February 24, 2004, Bodisen International, Inc. (※BII§), the non-operative holding company of BBST (accounting acquirer) consummated a merger agreement with Stratabid.com, Inc. (legal acquirer) (※Stratabid§), a Delaware corporation, to exchange 12,000,000 shares of Stratabid to the stockholders of BII, in which BII merged into Bodisen Holdings, Inc. (BHI), an acquisition subsidiary of Stratabid, with BHI being the surviving entity. As a part of the merger, Stratabid cancelled 3,000,000 shares of its issued and outstanding stock owned by its former president and declared a stock dividend of three shares on each share of its common stock outstanding for all stockholders on record as of February 27, 2004.
Stratabid was incorporated in the State of Delaware on January 14, 2000 and before the merger, was a start- up stage Internet based commercial mortgage origination business based in Vancouver, BC, Canada.
The exchange of shares with Stratabid has been accounted for as a reverse acquisition under the purchase method of accounting because the stockholders of BII obtained control of Stratabid. On March 1, 2004, Stratabid was renamed Bodisen Biotech, Inc. (the ※Company§). Accordingly, the merger of the two companies has been recorded as a recapitalization of the Company, with the Company (BII) being treated as the continuing entity. The historical financial statements presented are those of BII.
As a result of the reverse merger transaction described above the historical financial statements presented are those of BBST, the operating entity.
In March 2005, Bodisen Biotech Inc. completed a $3 million convertible debenture private placement through an institutional investor. Approximately $651,000 in incremental and direct expenses relating to this private placement has been amortized over the term of the convertible debenture. None of the expenses were paid directly to the institutional investor. The net proceeds from this offering were invested as initial start-up capital in a newly created wholly-owned Bodisen subsidiary by the name of ※Yang Ling Bodisen Agricultural Technology Co., Ltd. (※Agricultural§). In June 2005, Agricultural completed a transaction with Yang Ling Bodisen Biology Science and Technology Development Company Limited (※BBST§), Bodisen Biotech, Inc.*s operating subsidiary in China, which resulted in Agricultural owning 100% of BBST.
In June 2006, BBST created another wholly owned subsidiary in the Uygur autonomous region of Xinjiang, China by the name of Bodisen Agriculture Material Co. Ltd. (※Material§). Material had no operations during the year ended December 31, 2006.
Basis of Presentation
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company*s functional currency is the Chinese Renminbi; however the accompanying consolidated financial statements have been translated and presented in United States Dollars ($).
Foreign Currency Translation
As of December 31, 2007 and 2006, the accounts of the Company were maintained, and their consolidated financial statements were expressed in the Chinese Yuan Renminbi (CNY). Such consolidated financial statements were translated into U.S. Dollars (USD) in accordance with Statement of Financial Accounts Standards ("SFAS") No. 52, "Foreign Currency Translation," with the CNY as the functional currency. According to the Statement, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholder's equity is translated at the historical rates and statement of operations items are translated at the weighted average exchange rate for the year. The resulting translation adjustments are reported under other comprehensive income in accordance with SFAS No. 130, "Reporting Comprehensive Income.§
Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. However, as discussed in Note 19, there are certain law suits filed by investors against the Company and the Company is subject to potential claims from certain investors who have a right to receive the Company*s shares. These conditions raise substantial doubt about the Company's ability to continue as a going concern.
Management's responses in regard to these matters are also described in Note 19. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Note 2 每 Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.
Accounts Receivable
The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Terms of the sales vary from COD through a credit term up to 9 to 12 months. Reserves are recorded primarily on a specific identification basis. Allowance for doubtful accounts amounted to $25,447,689 and $659,653 at December 31, 2007 and 2006, respectively.
Advances to Suppliers
The Company makes advances to certain vendors for purchase of its material. The advances to suppliers are interest free and unsecured. The advances to suppliers amounted to $9,741,090 and $12,662,139 at December 31, 2007 and 2006, respectively.
Inventories
Inventories are valued at the lower of cost (determined on a weighted average basis) or market. The Management compares the cost of inventories with the market value and allowance is made for writing down their inventories to market value, if lower.
Loan Receivable
In August 2006, the Company entered into an agreement to loan $1,306,745 to an unrelated party. The loan is unsecured, payable by August 2008 and carries an interest rate of 13% per annum. Interest receivable on this loan was $192,472 and $68,191 at December 31, 2007 and 2006, respectively.
In November 2006, the Company entered into an agreement to loan $814,096 to an unrelated party. The loan is unsecured, payable by November 2008 and carries an interest rate of 13% per annum. Interest receivable on this loan was $125,962 and $6,214, at December 31, 2007 and 2006, respectively.
Property & Equipment & Capital Work In Progress
Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives of:
Operating equipment 10 years
Vehicles 8 years
Office equipment 5 years
Buildings 30 years
At December 31, 2007 and 2006, the following are the details of the property and equipments:
|
2007 |
2006 |
|
$ |
$ |
|
|
|
Operating equipment |
1,025,862 |
946,252 |
Vehicles |
722,360 |
597,239 |
Office equipment |
81,671 |
74,944 |
Buildings |
4,735,665 |
4,426,559 |
|
---------------- |
---------------- |
|
6,565,558 |
6,044,994 |
Less accumulated depreciation |
(1,259,304) |
(849,711) |
|
---------------- |
---------------- |
|
5,306,254 |
5,195,283 |
|
========= |
========= |
Depreciation expense for the years ended December 31, 2007 and 2006 was $336,610 and $307,310, respectively.
On December 31, 2007 and 2006, the Company has ※Capital Work in Progress§ representing the construction in progress of the Company*s manufacturing plant amounting $7,722,756 and $3,669,807, respectively.
Marketable Security
Marketable security consists of 2,063,768 shares of China Natural Gas, Inc. (traded on the OTCBB: CHNG). This investment is classified as available for-sale as the Company plans to hold this investment for the long-term. This investment is reported at fair value with unrealized gains and losses included in other comprehensive income. The fair value is determined by using the securities quoted market price as obtained from stock exchanges on which the security trades.
Investment income, principally dividends, is recorded when earned. Realized capital gains and losses are calculated based on the cost of securities sold, which is determined by the "identified cost" method.
Long-Lived Assets
Effective January 1, 2002, the Company adopted Statement of Financial Accounting Standards No. 144, ※Accounting for the Impairment or Disposal of Long-Lived Assets§ (※SFAS 144§), which addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supersedes SFAS No. 121, ※Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of,§ and the accounting and reporting provisions of APB Opinion No. 30, ※Reporting the Results of Operations for a Disposal of a Segment of a Business.§ The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with SFAS 144. SFAS 144 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets* carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. Based on its review, the Company believes that, as of December 31, 2007 there were no significant impairments of its long-lived assets.
Intangible Assets
Intangible assets consist of Rights to use land and Fertilizers proprietary technology rights. The Company evaluates intangible assets for impairment, at least on an annual basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability of intangible assets, other long-lived assets and, goodwill is measured by comparing their net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss.
Fair Value of Financial Instruments
Statement of financial accounting standard No. 107, Disclosures about fair value of financial instruments, requires that the Company disclose estimated fair values of financial instruments. The carrying amounts reported in the statements of financial position for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.
Revenue Recognition
The Company*s revenue recognition policies are in compliance with Staff accounting bulletin (SAB) 104. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectibility is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied
are recorded as unearned revenue.
The Company*s revenue is earned in three product lines, which are as follows
|
For the Years Ended December 31, |
|
2007 |
2006 |
|
$ |
$ |
|
|
|
Compound fertiliser |
5,882,663 |
27,380,650 |
Liquid fertiliser |
4,225,933 |
7,465,830 |
Pesticide |
1,999,983 |
8,780,504 |
|
---------------------- |
---------------------- |
|
12,108,579 |
43,626,984 |
|
============ |
============ |
Advertising Costs
The Company expenses the cost of advertising as incurred or, as appropriate, the first time the advertising takes place. Advertising costs for the years ended December 31, 2007 and 2006 were insignificant.
Stock-Based Compensation
The Company adopted SFAS No. 123 (Revised 2004), Share Based Payment (※SFAS No. 123R§), under the modified-prospective transition method on January 1, 2006. SFAS No. 123R requires companies to measure and recognize the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value. Share-based compensation recognized under the modified-prospective transition method of SFAS No. 123R includes share-based compensation based on the grant-date fair value determined in accordance with the original provisions of SFAS No. 123, Accounting for Stock-Based Compensation, for all share-based payments granted prior to and not yet vested as of January 1, 2006 and sharebased compensation based on the grant-date fair-value determined in accordance with SFAS No. 123R for all share-based payments granted after January 1, 2006. SFAS No. 123R eliminates the ability to account for the award of these instruments under the intrinsic value method prescribed by Accounting Principles Board (※APB§) Opinion No. 25, Accounting for Stock Issued to Employees, and allowed under the original provisions of SFAS No. 123. Prior to the adoption of SFAS No. 123R, the Company accounted for our stock option plans using the intrinsic value method in accordance with the provisions of APB Opinion No. 25 and related interpretations.
Primarily as a result of adopting SFAS No. 123R, the Company recognized $7,523 in share-based compensation expense for the year ended December 31, 2006. There were no new employee options granted during the year ended December 31, 2006; however, the expense recognized of $7,523 relates to the vesting of options issued to employees prior to January 1, 2006. The impact of this share-based compensation expense on the Company*s basic and diluted earnings per share was $0.00 per share. The fair value of our stock options was estimated using the Black-Scholes option pricing model.
For periods presented prior to the adoption of SFAS No. 123R, pro forma information regarding net income and earnings per share as required by SFAS No. 123R has been determined as if we had accounted for our employee stock options under the original provisions of SFAS No. 123. The fair value of these options was estimated using the Black-Scholes option pricing model. For purposes of pro forma disclosure, the estimated fair value of the options is amortized to expense over the option*s vesting period. The pro forma expense to recognize during the year ended December 31, 2005 is presented in Note 12.
Income Taxes
The Company utilizes SFAS No. 109, ※Accounting for Income Taxes,§ which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realised.
According to the Provisional Regulations of the People*s Republic of China on Income Tax, the Document of Reductions and Exemptions of Income Tax for the Company had been approved by the local tax bureau and the Yang Ling Agricultural High-Tech Industries Demonstration Zone. The Company was exempted from income tax through October 2007.
In March 2005, Bodisen Biotech Inc. formed Agricultural. Under Chinese law, a newly formed wholly owned subsidiary of a foreign company enjoys an income tax exemption for the first two years and a 50% reduction of normal income tax rates for the following 3 years. In order to extend such tax benefits, in June 2005, Agricultural completed a transaction with BBST, which resulted in Agricultural owning 100% of BBST.
If the Company had not been exempt from paying income taxes during the years ended December 31, 2007 and 2006, income tax expense would have been approximately $0 and $4,668,000, respectively, and earnings per share would have been reduced by $0.0 and $0.26, respectively.
Foreign Currency Transactions and Comprehensive Income
Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company is Chinese Renminbi. The unit of Renminbi is in Yuan. Translation gains of $5,148,122 and $1,798,387 at December 31, 2007 and 2006, respectively, are classified as an item of other comprehensive income in the stockholders* equity section of the consolidated balance sheet. During the years ended December 31, 2007 and 2006, other comprehensive income in the consolidated statements of operations and other comprehensive income included translation gains of $3,349,735 and $1,210,466, respectively.
Basic and Diluted Earnings Per Share
Earnings per share is calculated in accordance with the Statement of Financial Accounting Standards No. 128 (SFAS No. 128), ※Earnings per share.§ SFAS No. 128 superseded Accounting Principles Board Opinion No.15 (APB 15). Net loss per share for all periods presented has been restated to reflect the adoption of SFAS No. 128. Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
Statement of Cash Flows
In accordance with Statement of Financial Accounting Standards No. 95, ※Statement of Cash Flows,§ cash flows from the Company*s operations are calculated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.
Segment Reporting
Statement of Financial Accounting Standards No. 131 (※SFAS 131§), ※Disclosure About Segments of an Enterprise and Related Information§ requires use of the ※management approach§ model for segment reporting. The management approach model is based on the way a company*s management organizes segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. SFAS 131 has no effect on the Company*s consolidated financial statements as the Company consists of one reportable business segment. All revenue is from customers in People*s Republic of China. All of the Company*s assets are located in People*s Republic of China.
Reclassifications
Certain prior period amounts have been reclassified to conform to the year ended December 31, 2007 presentation.
Recent Pronouncements
In September 2006, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 108, ※Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,§ (※SAB 108§),which provides interpretive guidance on the consideration of the effects of prior year misstatements in quantifying current year misstatements for the purpose of a materiality assessment. The Company adopted SAB 108 in the fourth quarter of 2006 with no impact on its consolidated financial statements. In September 2006, FASB issued SFAS 157 "Fair Value Measurements.§ This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This Statement applies under other accounting pronouncements that require or permit fair value measurements, the Board having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this Statement does not require any new fair value measurements. However, for some entities, the application of this Statement will change current practice. This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The management is currently evaluating the effect of this pronouncement on the Company*s financial statements.
In September 2006, FASB issued SFAS 158 ※Employers* Accounting for Defined Benefit Pension and Other Postretirement Plans〞an amendment of FASB Statements No. 87, 88, 106, and 132(R).§ This Statement improves financial reporting by requiring an employer to recognize the overfunded or underfunded status of a defined benefit postretirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position and to recognize changes in that funded status in the year in which the changes occur through comprehensive income of a business entity or changes in unrestricted net assets of a not-for-profit organization. This Statement also improves financial reporting by requiring an employer to measure the funded status of a plan as of the date of its year-end statement of financial position, with limited exceptions. An employer with publicly traded equity securities is required to initially recognize the funded status of a defined benefit postretirement plan and to provide the required disclosures as of the end of the fiscal year ending after December 15, 2006. An employer without publicly traded equity securities is required to recognize the funded status of a defined benefit postretirement plan and to provide the required disclosures as of the end of the fiscal year ending after June 15, 2007. However, an employer without publicly traded equity securities is required to disclose the following information in the notes to financial statements for a fiscal year ending after December 15, 2006, but before June 16, 2007, unless it has applied the recognition provisions of this Statement in preparing those financial statements. The requirement to measure plan assets and benefit obligations as of the date of the employer*s fiscal year-end statement of financial position is effective for fiscal years ending after December 15, 2008. The management is currently evaluating the effect of this pronouncement on the Company*s financial statements.
In February of 2007 the FASB issued SFAS 159, ※The Fair Value Option for Financial Assets and Financial Liabilities〞Including an amendment of FASB Statement No. 115.§ The statement permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. The statement is effective as of the beginning of an entity*s first fiscal year that begins after November 15, 2007. The Company is analyzing the potential accounting treatment.
In December 2007, the FASB issued SFAS No. 160, ※Noncontrolling Interests in Consolidated Financial Statements,§ which is an amendment of Accounting Research Bulletin (※ARB§) No. 51. This statement clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. This statement changes the way the consolidated income statement is presented, thus requiring consolidated net income to be reported at amounts that include the amounts attributable to both parent and the noncontrolling interest. This statement is effective for the fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. Based on current conditions, the Company does not expect the adoption of SFAS 160 to have a significant impact on its results of operations or financial position.
In December 2007, the FASB issued SFAS No. 141 (revised 2007), ※Business Combinations.§ This statement replaces FASB Statement No. 141, ※Business Combinations.§ This statement retains the fundamental requirements in SFAS 141 that the acquisition method of accounting (which SFAS 141 called the purchase method) be used for all business combinations and for an acquirer to be identified for each business combination. This statement defines the acquirer as the entity that obtains control of one or more businesses in the business combination and establishes the acquisition date as the date that the acquirer achieves control. This statement requires an acquirer to recognize the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the statement. This statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. The Company does not expect the adoption of SFAS 160 to have a significant impact on its
results of operations or financial position.
FASB Interpretation 48 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Benefits from tax positions should be recognized in the financial statements only when it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority that would have full knowledge of all relevant information. The amount of tax benefits to be recognized for a tax position that meets the more-likely-than-not recognition threshold is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Tax benefits relating to tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent financial reporting period in which that threshold is met or certain other events have occurred. Previously recognized tax benefits relating to tax positions that no longer meet the more-likely-than-not recognition threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met. Interpretation 48 also provides guidance on the accounting for and disclosure of tax reserves for unrecognized tax benefits, interest and penalties and accounting in interim periods. Interpretation 48 is effective for fiscal years beginning after December 15, 2006. The change in net assets as a result of applying this pronouncement will be a change in accounting principle with the cumulative effect of the change required to be treated as an adjustment to the opening balance of retained earnings on January 1, 2007, except in certain cases involving uncertainties relating to income taxes in purchase business combinations. In such instances, the impact of the adoption of Interpretation 48 will result in an adjustment to goodwill. The adoption of this standard had no material impact on the Company*s consolidated financial statements.
Note 3 每 Principles of Consolidation
The accompanying consolidated financial statements include the accounts of Bodisen Biotech, Inc., its 100% wholly-owned subsidiaries, Bodisen Holdings, Inc. (BHI), Yang Ling Bodisen Agricultural Technology Co., Ltd (Agricultural), which was incorporated in March 2005, and Bodisen Agriculture Material Co., Ltd. (Material), which was incorporated in June 2006, as well as the accounts of BHI*s 100% wholly-owned subsidiary, Yang Ling Bodisen Biology Science and Technology Development Company Limited (BBST). All significant inter-company accounts and transactions have been eliminated in consolidation.
Note 4 每 Advances to officers
During the six month period ending June 30, 2005, the Company advanced $2,383,217 to 4 officers as a short term loan. Said loan was interest free, unsecured, and payable upon demand. These loans were repaid during the quarter ended September 30, 2005.
Note 5 - Inventory
The inventory as of December 31, 2007 and 2006 consisted of the following :-
|
2007 |
2006 |
|
$ |
$ |
|
|
|
Raw material |
425,542 |
1,257,883 |
Packaging |
250,018 |
161,923 |
Finished Goods |
691,730 |
550,280 |
Consumables |
336 |
395 |
|
---------------- |
---------------- |
|
1,367,626 |
1,970,481 |
Less: Obsolescence Reserve |
(188,178) |
(175,896) |
|
---------------- |
---------------- |
Net Inventory |
1,179,448 |
1,794,585 |
|
========= |
========= |
Note 6 每 Marketable Security
During the year ended December 31, 2005, the Company purchased 2,063,768 shares of China Natural Gas, Inc. (traded on the OTCBB: CHNG) for $2,867,346. At December 31, 2007 and 2006, the fair value of this investment was $14,239,999 and $6,500,869, respectively, which resulted in an unrealized gain (loss) of $7,739,130 and ($309,565) for the years ended December 31, 2007 and 2006, respectively, which is included in other comprehensive income. At December 31, 2006, this represented a 7.1% interest in China Natural Gas, Inc. The CEO of China Natural Gas was a former board member of the Company. See Note 19 for litigation regarding these shares of common stock of China Natural Gas.
Note 7 每Other Long-term Assets
During the year ended December 31, 2006, the Company acquired a 19.5% and a 19.8% interest in two local companies by investing a total amount of $1,156,861 in cash.
In August, 2006, the Company entered into a land lease agreement for 30 years. The annual lease expense approximately amounts to $169,580. The lease expense for the next 15 years amounting to $2,529,818 has been prepaid on signing of the agreement. The payment schedule for the remaining 15 years as follows
- in November, 2021 每 prepayment for next 8 years commencing on November 2021 and
- in November, 2029 每 prepayment of remaining 7 years commencing on November 2029
The land lease prepayment as of December 31, 2007 and 2006 can be summarised as follows:
|
2007 |
2006 |
|
$ |
$ |
|
|
|
Prepaid Lease (for 15 years) |
2,617,962 |
2,569,818 |
Current portion |
185,344 |
173,246 |
|
---------------------- |
---------------------- |
Long-term portion |
2,432,618 |
2,396,572 |
|
============ |
============ |
The amortization expense as of December 31, 2007 and 2006 was $185,344 and $28,264, respectively.
Amortization expense for the prepayment of land lease over the next five fiscal years is estimated to be: 2008-$169,500, 2009-$169,500, 2010- $169,500, 2011-$169,500 and 2012-$169,500.
Note 8 每 Intangible Assets
Net intangible assets at December 31, 2007 and 2006 were as follows:
|
2007 |
2006 |
|
$ |
$ |
|
|
|
Rights to use land |
1,873,929 |
1,768,386 |
Fertilisers proprietary technology rights |
1,096,704 |
1,025,120 |
|
---------------------- |
---------------------- |
|
2,970,633 |
2,793,506 |
Less Accumulated amortisation |
(919,981) |
(739,160) |
|
---------------------- |
---------------------- |
|
2,050,652 |
2,054,346 |
|
============ |
============ |
The Company*s office and manufacturing site is located in Yang Ling Agricultural High-Tech Industries Demonstration Zone in the province of Shaanxi, People*s Republic of China. The Company leases land per a real estate contract with the government of People*s Republic of China for a period from November 2001 through November 2051. Per the People*s Republic of China*s governmental regulations, the Government owns all land.
During July 2003, the Company leased another parcel of land per a real estate contract with the government of the People*s Republic of China for a period from July 2003 through June 2053.
The Company has recognized the amounts paid for the acquisition of rights to use land as intangible asset and amortizing over a period of fifty years. The ※Rights to use land§ is being amortized over a 50 year period.
The Company acquired Fluid and Compound Fertilizers proprietary technology rights with a life ending December 31, 2011. The Company is amortizing these proprietary technology rights over a period of ten years.
Amortisation expense for the Company*s intangible assets for the years ended December 31, 2007 and 2006 amounted to $141,416 and $134,636, respectively.
Amortization expense for the Company*s intangible assets over the next five fiscal years is estimated to be: 2008-$130,000, 2009-$130,000, 2010- $130,000, 2011-$130,000 and 2012-$130,000.
Note 9 每 Note Payable
On December 8, 2005, the Company issued a $5,000,000 note payable to Amaranth Partners LLC that accrued interest at 9% per annum and was due on March 8, 2006. In connection with this note payable agreement, the Company also issued to Amaranth Partners LLC a warrant to purchase 133,333 shares of the Company*s common stock for $7.50 per share. The Company first determined the value of the note and the fair value of the detachable warrants issued in connection with this note payable. The estimated value of the warrants of $968,282 was determined using the Black-Scholes option pricing model and the following assumptions: term of 5 years, a risk free interest rate of 4.00%, a dividend yield of 0% and volatility of 31%. The face amount of the note payable of $5,000,000 was proportionately allocated to the note payable and the warrant in the amount of $4,188,810 and $811,190, respectively. The amount allocated to the warrants of $811,190 was recorded as a discount on the note payable and will be amortized over the year life of the note payable. For the year ended December 31, 2006 $603,886, had been amortized to interest expense. The $5,000,000 note plus $112,500 of
accrued interest were repaid in March 2006.
Note 10 每 Convertible Debenture
On March 16, 2005, the Company completed a private placement offering. The Company received $3,000,000 and issued a one year 9% debenture convertible into shares of common stock by dividing the aggregate principal and accrued interest by a conversion price of $4.80; and three year warrants to purchase 187,500 shares of common stock at $4.80 per share and three year warrants to purchase 40,000 shares of common stock at $6.88
per share.
This debenture was considered to have an embedded beneficial conversion feature because the conversion price was less than the quoted market price at the time of the issuance. The Company allocated the proceeds of the debt between the warrant and the debt based on relative fair values, which amounted to $365,881 and $2,634,119. The beneficial conversion feature of $803,381 was recorded separately based on the intrinsic value method per EITF 00-27. During the year ended December 31, 2005, the entire $3,000,000 convertible debenture and $155,564 of accrued interest were converted into 657,402 shares of the Company*s common stock. In addition, because the entire principal balance of the convertible debenture was converted into common stock, the entire debt discount of $1,169,262 was amortized to interest expense.
Note 11 每 Stockholders* Equity
During the year ended December 31, 2005, the Company issued 657,402 shares of its common stock in connection with the conversion of a $3,000,000 convertible debenture and $155,564 of accrued interest. In addition, the Company also issued 195,500 shares of common stock upon the exercise of warrants and received proceeds of $955,040.
On February 3, 2006, the Company entered into a placing agreement (the "Placing Agreement") with Charles Stanley & Company Limited ("Charles Stanley§) relating to the sale of up to 1,643,836 shares of the Company's common stock. Pursuant to the Placing Agreement, Charles Stanley agreed to use its reasonable efforts to sell all such shares of common stock at a price of 730 pence (approximately US$12.99) per share, resulting in gross proceeds of approximately 12 million British pounds sterling (US$21,360,005). The Company incurred offering costs and expenses of $5,144,356 related to this sale of common stock. Of this amount $3,385,481 was paid to a firm that is associated with Benjamin Wey (who is the president of New York Global Group).
In connection with the placement, the Company's shares were admitted to trading on the AIM Market of the London Stock Exchange. The Company's shares continued to be listed on the American Stock Exchange at such time.
On March 15, 2006, the Company completed financing of $5,322,506 by issuing 380,179 restricted shares of common stock of the Company at $14.00 per share to institutional investors in a private placement pursuant to Regulation S. The Company incurred offering costs and expenses of $988,351 related to this sale of common stock. Of this amount $778,346 was paid to a firm that is associated with Benjamin Wey. The proceeds from this financing were used to repay the $5 million short term note that the Company entered in December 2005.
During the year ended December 31, 2006, 165,333 warrants were exercised and the Company received proceeds of $1,220,160.
Prior to the Company effectuating a reverse merger, various individuals (the ※Investors§) provided investment capital to a predecessor entity. After its formation, the Company issued share certificates of common stock to reflect the value of these investments. Pursuant to apparent agreement with the Investors, the Company issued the share certificates to certain individuals other than the Investors, including two officers of the Company, who held title to those shares as nominee for the benefit of the Investors. In late 2005, some of the Investors began to request that the beneficially-held shares be transferred to them so that they could hold the shares in their own names. All of the shares thus owned were transferred with the exception of approximately 738,000 shares.
The nominees apparently do not assert any interest in or make any claim to the remaining shares. The Company holds the original certificates representing approximately 738,000 shares in its office in Xi*an, China, for the benefit of the Investors or their assigns. The Company does not contest the rights of the appropriate investors on the certificate and remains willing to effectuate the transfer of the shares to appropriate investors or their assigns as the law allows. The record holders of the share certificates do not dispute the rights of the affected investors to receive the transfer of the shares as the law permits.
The Company is not aware that any of the Investors has expressed the right to receive any monetary compensation in the form of damages, interest or otherwise in connection with the delivery of the shares. In consequence, the Company expresses no view as to whether or not an unfavorable outcome would be probable or remote or provide an estimate or range of potential loss if the outcome were unfavorable in the event that an Investor or Investors asserts a claim.
Note 12 每 Stock Options and Warrants
Stock Options
In December 2002, the FASB issued SFAS No. 148 ※Accounting for Stock Based Compensation- Transition and Disclosure.§ SFAS No. 148 amends SFAS No. 123, ※Accounting for Stock Based Compensation,§ to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosure requirements of Statement 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used, on reported results. The Statement is effective for the Companies* interim reporting period ending January 31, 2003.
In compliance with FAS No. 148, the Company has elected to continue to follow the intrinsic value method in accounting for its stock-based employee compensation plan as defined by APB No. 25 and has made the applicable disclosures below.
In 2004 the board of directors approved the creation of the 2004 Stock Option Plan. This plan provides for the grant of incentive stock options to employees, directors and consultants. Options issued under this plan will expire over a maximum term of five years from the date of grant.
Pursuant to the Stock Option Plan, during the year ended December 31, 2004, the Company granted 110,000 stock options to two directors (55,000 options each), of which 100,000 stock options were granted on June 4, 2004 and the balance of the 10,000 was granted on December 28, 2004.
On the first 100,000 stock options granted, 50,000 stock options vested immediately and 50,000 stock options became vested over 8 equal quarterly installments, with the first installment vesting at the end of the second quarter of 2004. The 10,000 stock options granted on December 28, 2004 vested on December 31, 2004.
The option exercise price was $5 for the first 100,000 stock options, which was the same as fair value of the shares at the time of granting of the options. The option exercise price was $5.80 for the second 10,000 stock options, which was the same as fair value of the shares at the time of granting of the options.
On October 4, 2005, the Company granted 26,000 stock options to two directors (13,000 options each). 20,000 stock options vested immediately and the remaining 6,000 stock options became vested over the next three months. The option exercise price was $6.72, which was the same as fair value of the shares at the time of granting of the options.
Following is a summary of the stock option activity:
|
Options outstanding |
Weighted Average Exercise Price |
Aggregate Intrinsic Value |
|
|
$ |
|
|
|
|
|
Outstanding, December 31, 2006 |
136,000 |
5.39 |
50,000 |
Granted |
- |
- |
|
Forfeited |
- |
- |
|
Exercised |
- |
- |
|
|
---------------- |
|
|
Outstanding, December 31, 2007 |
136,000 |
5.39 |
0 |
|
========= |
|
|
Following is a summary of the status of options outstanding at December 31, 2007:
Outstanding Options
|
Exercisable Options |
Exercise price |
Number |
Average Remaining Contractual Life |
Average Exercise Price |
Number |
Average Exercise Price |
|
|
|
|
|
|
$5.00 |
100,000 |
1.42 |
$5.00 |
93,750 |
$5.00 |
$5.80 |
10,000 |
1.99 |
$5.80 |
10,000 |
$5.80 |
$6.72 |
26,000 |
2.76 |
$6.72 |
24,000 |
$6.72 |
Warrants
Following is a summary of the warrant activity:
|
Options outstanding |
|
|
Outstanding, December 31, 2005 |
165,333 |
Granted |
- |
Forfeited |
- |
Exercised |
(165,333) |
|
---------------- |
Outstanding, December 31, 2006 |
- |
Granted |
- |
Forfeited |
- |
Exercised |
- |
|
---------------- |
Outstanding, December 31, 2007 |
- |
|
========= |
Note 13 每 Supplemental Disclosure of Cash Flows
The Company prepares its statements of cash flows using the indirect method as defined under SFAS No. 95.
The Company paid $4,318 and $112,500 of interest and $0 and $0 of income taxes during the years ended December 31, 2007 and 2006, respectively.
Note 14 每 Employee Welfare Plans
The Company has established its own employee welfare plan in accordance with Chinese law and regulations. The Company makes annual contributions of 14% of all employees* salaries to the employee welfare plan. The total expense for the welfare plan was $0 and $3,713 for the years ended December 31, 2007 and 2006, respectively. The Company has recorded welfare payable of $71,908 and $263,064 at December 31, 2007 and 2006, respectively, which is included in accrued expenses in the accompanying consolidated balance sheet.
Note 15 每 Statutory Common Welfare Fund
As stipulated by the Company Law of the People*s Republic of China (PRC), net income after taxation can only be distributed as dividends after appropriation has been made for the following:
- Making up cumulative prior years* losses, if any;
- Allocations to the ※Statutory surplus reserve§ of at least 10% of income after tax, as determined under PRC accounting rules and regulations, until the fund amounts to 50% of the Company*s registered capital;
- Allocations of 5-10% of income after tax, as determined under PRC accounting rules and regulations, to the Company*s ※Statutory common welfare fund§, which is established for the purpose of providing employee facilities and other collective benefits to the Company*s employees; and
- Allocations to the discretionary surplus reserve, if approved in the stockholders* general meeting.
Pursuant to the new Corporate Law effective on January 1, 2006, there is now only one "Statutory surplus reserve" requirement. The reserve is 10 percent of income after tax, not to exceed 50 percent of registered capital.
Pursuant to the "Circular of the Ministry of Finance ( MOF) on the Issue of Corporate Financial Management after the Corporate Law Enforced" (No.67 [2006]), effective on April 1, 2006, issued by the MOF, the companies will transfer the balance of SCWF as of December 31, 2005 to Statutory Surplus Reserve. Any deficit in the SCWF will be charged in turn to Statutory Surplus Reserve, additional paid-in capital and undistributed profit of previous years. If a deficit still remains, it should be transferred to retained earnings and be reduced to zero by a transfer from after tax profit of following years. At December 31, 2006, the Company did not have a deficit in the SCWF.
The Company has appropriated $0 and $1,947,557 as reserve for the statutory surplus reserve and welfare fund for the years ended December 31, 2007 and 2006, respectively.
Note 16 每 Factory Location and Lease Commitments
BBST*s principal executive offices are located at North Part of Xinquia Road, Yang Ling Agricultural High-Tech Industries Demonstration Zone Yang Ling, Shaanxi province, People*s Republic of China. BBST owns two factories, which includes three production lines, an office building, one warehouse, and two research labs and, is located on 10,900 square meters of land. These leases require monthly rental payments of $2,180 and the leases expire in 2013.
Note 17 每 Earnings Per Share
Earnings per share for years ended December 31, 2007 and 2006 were determined by dividing net income for the periods by the weighted average number of both basic and diluted shares of common stock and common stock equivalents outstanding.
The following is an analysis of the differences between basic and diluted earnings per common share in accordance with Statement of Financial Accounting Standards No. 128, ※Earnings Per Share.§
|
Year Ended December, 31 |
|
|
2007 |
|
|
2006 |
|
|
Income |
Shares |
Per
Share |
Income |
Shares |
Per
Share |
|
|
|
|
|
|
|
Basic earnings per share |
|
|
|
|
|
|
|
---------------- |
|
|
--------------- |
|
|
Net income (loss) |
$(25,327,392) |
|
|
$13,730,827 |
|
|
|
========= |
|
|
========= |
|
|
Weighted shares outstanding |
|
18,310,250 |
|
|
17,966,090 |
|
|
|
|
-------------- |
|
|
-------------- |
|
|
|
$(1.38) |
|
|
$0.76 |
|
|
|
======= |
|
|
======= |
Diluted earnings per share |
|
|
|
|
|
|
|
---------------- |
|
|
---------------- |
|
|
Net income (loss) |
$(25,327,392) |
|
|
$13,730,827 |
|
|
|
========= |
|
|
========= |
|
|
|
|
|
|
|
|
|
Weighted shares outstanding |
|
18,310,250 |
|
|
17,966,090 |
|
|
|
|
|
|
|
|
Effect of dilutive securities |
|
|
|
|
|
|
Options |
|
|
|
|
66,074 |
|
Warrants |
|
|
|
|
40,269 |
|
|
|
-------------- |
|
|
-------------- |
|
|
|
|
|
|
18,072,433 |
|
|
|
======= |
|
|
======= |
|
|
|
|
-------------- |
|
|
-------------- |
|
|
|
$(1.38) |
|
|
$0.76 |
|
|
|
======= |
|
|
======= |
|
|
|
|
|
|
|
Note 18 每 Current Vulnerability Due to Certain Concentrations
Two vendors provided 70.3% and 10.5% of the Company*s raw materials for the year ended December 31, 2007. Three vendors provided 47.5%, 17.7% and 12.5% of the Company*s raw materials for the year ended December 31, 2006. Four vendors provided 29.9%, 22.4%, 11.6% and 11.2% of the Company*s raw materials for the year ended December 31, 2005.
The Company*s operations are carried out in the PRC. Accordingly, the Company*s business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, by the general state of the PRC*s economy. The Company*s business may be influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.
Note 19 每 Litigation
The Company is involved in a variety of claims, suits, investigations and proceedings that arise from time to time in the ordinary course of its business, including actions with respect to contracts, intellectual property (IP), product liability, employment, benefits, securities, and other matters. These actions may be commenced by a number of different constituents, including competitors, partners, clients, current or former employees, government and regulatory agencies, stockholders, and representatives of the locations in which it does business. The following is a discussion of some of the more significant legal matters involving the Company.
In late 2006, various shareholders of the Company filed eight purported class actions in the U.S. District Court for the Southern District of New York against the Company and certain of its officers and directors (among others), asserting claims under the federal securities laws. The complaints contain allegations about prior financial disclosures and its internal controls and a prior, now-terminated relationship with a financial advisor.
The eight actions are Stephanie Tabor vs. Bodisen, Inc., et al., Case No. 06-13220 (filed November 2006), Fraser Laschinger vs. Bodisen, Inc., et al., Case No. 06-13254 (filed November 2006), Anthony DeSantis vs. Bodisen, Inc., et. al., Case No. 06-13454 (filed November 2006), Yuchen Zhou vs. Bodisen, Inc., et. al., Case No. 06-13567 (filed November 2006), William E. Cowley vs. Bodisen, Inc., et. al., Case No. 06-13739 (filed December 2006), Ronald Stubblefield vs. Bodisen, Inc., et. al., Case No. 06-14449 (filed December 2006), Adam Cohen vs. Bodisen, Inc., et. al., Case No. 06- 15179 (filed December 2006) and Lawrence M. Cohen vs. Bodisen, Inc., et. al., Case No. 06-15399 (filed December 2006). Plaintiffs have not specified an amount of damages they seek. Last year, the Court consolidated each of the actions into a single proceeding.
About Bodisen Biotech, Inc.
Bodisen Biotech Inc. (the ※Company§) is a manufacturer of liquid and organic compound fertilizers, pesticides, insecticides and agricultural raw materials certified by the Petroleum Chemical Industry Administrative office of China (Chemical Petroleum Production Administrative Bureau), Shaanxi provincial government and Chinese government. The Company is headquartered in Shaanxi province and is a Delaware corporation. The Company's environmentally friendly ※green§ products have been proven to improve soil and plant quality, and increase crop yields.
SafeHarbor Statement
The press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Theses statements included financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future events, operations, products and services, and statement regarding future performance.
Forward-looking statements are generally identified by the words ※expect§, ※anticipates§, ※believes§, ※intends§, ※estimates§, ※plans§, and similar expressions. Although Bodisen Biotech, Inc.*s statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Bodisen Biotech, Inc., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC made by Bodisen Biotech, Inc., including those listed under ※risk Factors§ and ※Note Regarding Forward-Looking Statements§ in Bodisen Biotech, Inc.*s annual report on Form 10-K for the year ended December 31m 2007. Other than as required by applicable law, Bodisen Biotech, Inc. does not undertake any obligation to update or review any forward-looking information or statements.
Our website is located at http://www.bodisen.com.
A copy of our annual report on Form 10-K is available at:
http://www.sec.gov/Archives/edgar/data/1178552/000114420408022543/0001144204-08-022543-index.htm
Copies may also be obtained by contacting the Investor Relations Department at our corporate offices by calling +86-29-87882072 or by sending an e-mail message to info@bodisen.com.
Enquiries:
Charles Stanley Securities
(Nominated Adviser)
Richard Thompson / Philip Davies 020 7149 6000
Bodisen Biotech, Inc.
Scott King 001 219 939 3073
|